
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $275K | — | +1275.0% |
| SG&A Expense | $1.9M | — | +214.4% |
| Operating Income | -$8.2M | — | -1228.8% |
| Pre-tax Income | -$7.4M | — | -567.3% |
| Income Tax | -$23K | — | — |
| Net Income | -$6.6M | — | -451.6% |
| EPS (Basic) | -$10.74 | — | — |
| EPS (Diluted) | -$10.74 | — | -2653.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $4.3M | +12.2% | +57.8% |
| Short-term Investments | $1.9M | +695.8% | +727.0% |
| Accounts Receivable | $130K | -3.0% | -33.3% |
| Current Assets | $8.2M | +36.7% | +89.7% |
| Total Assets | $16.4M | -19.6% | +122.7% |
| Current Liabilities | $1.7M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.4M | — | -75.4% |
| Capital Expenditures | $71K | — | — |
| Investing Cash Flow | -$450K | — | +61.7% |
| Financing Cash Flow | $2.2M | — | -13.3% |
| Free Cash Flow | -$1.5M | — | — |
| +78.3% |
| Total Liabilities | $3.5M | -24.3% | -3.5% |
| Stockholders' Equity | $13.0M | -19.0% | +229.2% |